The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus

• Published in: BioMed research international Vol. 2019; no. 2019; pp. 1 - 8
• Main Authors: Ma, Jian-hua, Su, Xiao-fei, Jing, Ting, Sun, Rui, Kong, Xiao-cen, Xu, Xiao-hua, Li, Hui-qin, Wang, Jie, Ye, Lei
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2019; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Amplitudes; Analysis; Antidiabetics; Blood; Blood glucose; Blood pressure; Blood sugar; Blood sugar monitoring; Body mass index; Care and treatment; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes therapy; Drug dosages; Endocrinology; Enzymes; Fasting; Glucose; Glucose monitoring; Heart rate; Hyperglycemia; Hypoglycemia; Hypoglycemic agents; Insulin; Insulin resistance; Interleukin 6; Medical testing products; Patients; Peptides; Serum levels; Signal transduction; Standard deviation; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Type 2 diabetes; Variation; United States > US; China
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2019/2682657

Aim. To compare the effects of once-weekly Dulaglutide with once-daily glargine in poorly oral-antidiabetic controlled patients with type 2 diabetes mellitus (T2DM). Method. A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n=16) and glargine group (n=9). All patients received either Dulaglutide or glargine treatments for 52 weeks. Continuous glucose monitoring systems (CGMS) were applied to them for two 72 h periods at before and after the treatment each. Patient general clinical data were collected and analyzed. Result. Fast blood glucose (FBG) of the glargine group declined more significantly than the Dulaglutide group after treatment (p<0.05). The mean blood glucose (MBG), standard deviation of blood glucose (SDBG), mean amplitude of glycemic excursion (MAGE) within a day, the largest amplitude of glycemic excursion (LAGE), M-value, absolute means of daily difference (MODD) of glycemic excursion, the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9–7.8 mmol/L, and 9–10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p>0.05). The incidence of hypoglycemia was also similar between the two groups (p>0.05). Though serum levels of TNF-α, IL-6, and 8-PGF2α all decreased, significant reduction was found in TNF-α and 8-PGF2α. TNF-α was only significantly reduced in the Dulaglutide group, while 8-PGF2α was seen in both groups. Conclusion. For T2DM patients with poorly controlled oral antidiabetic drugs, once-weekly Dulaglutide not only has the same effect on glucose fluctuation as once-daily glargine but also significantly reduced TNF-α and 8-PGF2α after a 52 week treatment protocol. This trial is registered with ClinicalTrials.gov NCT01648582.